Thrombosis in Peripheral and Aneurysm Devices: Surface and Flow

Covered stents, flow diverters, endografts, and surgical grafts have expanded what can be treated outside the coronary tree. Thrombosis and graft occlusion remain among their most common modes of failure. In the femoropopliteal segment and infrainguinal bypass, primary patency is lost in roughly 20% to 40% of cases within one to three years, with thrombus and neointimal hyperplasia central to most of those events. On aneurysm bridging devices and endografts, late thrombus can produce distal emboli, sustain an endoleak, or prevent complete exclusion of the sac.

Across these different devices, the mechanisms converge on two factors. The first is the surface: how blood and tissue interact with the cover, and how healing proceeds along that interface. The second is the flow: how the geometry of the device and vessel shapes local hemodynamics. Systemic factors and antithrombotic therapy modify the risk, but the device and its deployment define the local environment in which thrombosis does or does not occur.

The surface problem

Within seconds of implantation, plasma proteins adsorb onto the polymer and metal. Platelets and leukocytes adhere and activate, and a fibrin-rich thrombus can form on any exposed region. In the favorable case, that early thrombus organizes and is covered by endothelium or neointima, converting a foreign surface into a more physiologic one. Several failure patterns recur. Inert covers endothelialize slowly, and human prosthetic grafts often remain without an endothelium for the life of the device, which leaves a persistently thrombogenic surface. At edges and anastomoses, low shear and chronic irritation drive neointimal hyperplasia, a process implicated in roughly half of late bypass failures. Some devices also sustain a chronic foreign-body reaction that destabilizes the interface and promotes late stenosis.

The flow problem

The second factor is mechanical. Kinking, underexpansion, diameter mismatch, and nonconformal edges create flow separation, recirculation, and stagnation. The femoropopliteal segment is the most demanding, because it flexes, twists, and compresses with every step. Stent fracture has been reported in more than a third of treated limbs in some series, and fracture is associated with restenosis and reocclusion. In aneurysm devices, abrupt changes in diameter, incomplete apposition, and gutter flow around the sealing zones create pockets of low flow at the neck and edges. Where flow is already slow, as in the veins and the inferior vena cava, any added obstruction can tip low flow into frank stasis.

The two factors that govern device thrombosis, and their shared endpoint.

Which factor dominates, and when

Both factors must be present for clinically significant thrombosis, but their relative weight shifts over time. In the early phase, within the first weeks to months, flow and mechanics dominate. A thromboresistant surface cannot compensate for a kinked, underexpanded, or poorly sealed device, so the priority is to eliminate gross mechanical defects through correct sizing, adequate landing zones, and conformal apposition. In the intermediate and late phase, over months to years, the biology of the interface governs durability. Neointimal hyperplasia at edges and anastomoses becomes the leading cause of late stenosis, and the character of that response is tied to surface chemistry, porosity, and the local inflammatory reaction.

A practical order of priorities: hemodynamics first, surface second, both together as the goal.

Design implications

The practical order follows from this. The first priority is hemodynamic, because mechanical defects account for most early failures. The second is a surface that supports controlled healing, rapid enough to reduce thrombogenicity yet not so aggressive that it produces occlusive hyperplasia. Strategies aimed at the surface with clinical support include heparin-bonded grafts, which improve primary patency relative to uncoated grafts, and dual-surface architectures that are tight on the luminal side to limit blood penetration and more open on the abluminal side to support tissue ingrowth. The third priority is integration, so that local shear and the cellular response are tuned together rather than treated as separate problems.

This polymer interface is the part of the device that Medibrane develops. We do not produce the metal frame. We engineer the cover, the coating, and the sealing membrane. The relevant levers are the ones described above: dual-surface porosity, conformal sealing membranes that close the gaps where thrombus begins, covalent adhesion that keeps a cover bonded to its frame, thickness control to within microns, and sutureless lamination that removes needle holes as a leak path. None of this substitutes for correct sizing or a sound landing zone. It addresses the other half of the problem, the surface, by design.

The conclusion is straightforward. Control the hemodynamics so the device survives its first months, and provide a surface it can heal into so it remains patent over years. Devices that achieve both will far less often have their outcome decided by thrombosis.

SELECTED REFERENCES

Schillinger M, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006.

Scheinert D, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005.

de Vries MR, et al. Vein graft failure: from pathophysiology to clinical outcomes. Nat Rev Cardiol. 2016.

Samson RH, et al.Heparin-bonded ePTFE femoropopliteal bypass grafts outperform ePTFE grafts without heparin.J Vasc Surg